Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 1, 2008, Pages 113-123

  Vassal, G ^a   Michel, G ^b   Esperou H ^c   Gentet, J C ^b   Valteau Couanet, D ^a   Doz, F ^d   Mechinaud, F ^e   Galambrun, C ^f   Neven, B ^g   Zouabi, H ^h   Nguyen, L ^h   Puozzo, C ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Hôpital d'Enfants   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d INSTITUT CURIE   (France)

^e HÔTEL DIEU   (France)

^f HÔPITAL DEBROUSSE   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; MELPHALAN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOTRANSPLANTATION; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; DRUG TARGETING; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLID TUMOR; STOMATITIS; TREATMENT OUTCOME; VALIDATION STUDY;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BODY WEIGHT; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MELPHALAN; MODELS, BIOLOGICAL; NEOPLASMS; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION;

EID: 34848829531     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0455-2     Document Type: Article

References (54)

1. Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, et al (2002) Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8(3):145-154
2. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, et al (2002) Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia Biol Blood Marrow Transplant 8(9):477-485
3. Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DSL, et al (2000) Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclosphosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 6:548-554
4. Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, et al (2001) Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 28(8):743-751
5. Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV, et al (2001) Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 28(11):1013-1018
6. Bostrom B, Enockson K, Johnson A, Bruns A, Blazar B (2003) Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. Pediatr Transplant 7(Suppl 3):12-18
7. Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O, et al (2003) In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 32(10):979-986
8. Chan SC, Liu CL, Lo CM, Lam BK, Lee EW, Wong Y, et al (2006) Estimating liver weight of adults by body weight and gender. World J Gastroenterol 12(14):2217-2222
9. Chan YL, Li CK, Chik KW, Law MY, Howard R (2005) Liver volume in thalassaemia major: relationship with body weight, serum ferritin, and liver function. Pediatr Radiol 35(2):165-168
10. Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD, et al (2001) Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 27(11):1121-1124
11. Dalle JH, Wall D, Theoret Y, Duval M, Shaw L, Larocque D, et al (2003) Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant 32(7):647-651
12. De Paepe ME, Carr SR, Cassese JA (2003) Postmortem validation of imaging-derived formulas for prediction of fetal lung volume. Fetal Diagn Ther 18(5):353-359
13. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al (1996) Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17(2):225-230
14. European Agency for the Evaluation of Medicinal Products HMEU (1997) Note for guidance on clinical investigation of medicinal products in children. CPMP/EWP/462/95
15. Food and Drug Administration (FDA) CfDERC (1998) General considerations for pediatric pharmacokinetic studies for drugs and biological products. Guidance for Industry (draft)
16. Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT (1999) Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos 27(12):1466-1469
17. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT (1997) Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 57(24):5509-5516
18. Grimley MS, Taylor C, Wall DA (2004) Frequency and magnitude of dose adjustment of i.v. busulfan in targeted dosing strategy for pediatrc allogeneic transplantation Bone Marrow Transplant 10:78
19. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, et al (1989) Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25(1):55-61
20. Grochow LB (1993) Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20(4 Suppl 4):18-25
21. Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, et al (1994) Busulfan bioavailability. Blood 84(7):2144-2150
22. Hassan M, Oberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, et al (1991) Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 28(2):130-134
23. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A (2005) Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl 11(12):1481-1493
24. Jones RJ, Lee KSK, Beschorner WE (1987) Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 44:778-783
25. Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, et al (2002) Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 8(9):493-500
26. Krivoy N, Hoffer E, Tabak A, Elhasid R, Arush MW, Stein J, et al (2002) Therapeutic monitoring of busulfan in pediatric bone marrow transplantation. Pediatr Hematol Oncol 19(1):31-37
27. Lee JH, Choi SJ, Lee JH, Kim SE, Park CJ, Chi HS, et al (2005) Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 84(5):321-330
28. Lindley C, Shea T, McCune J, Shord S, Decker J, Harvey D, et al (2004) Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. Anticancer Drugs 15(5):453-459
29. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G (1997) High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 20(11):909-913
30. McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR, et al (2002) Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 30(3):167-173
31. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118(4):255-267
32. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C (2004) I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 33(10):979-987
33. Nguyen L, Leger F, Lennon S, Puozzo C (2006) Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 57(2):191-198
34. Nguyen L (2006) The impact of switching from oral to IV busulfan on haematopoietic stem cell transplantation. EJHP Practice 12:58-59
35. Noda T, Todani T, Watanabe Y, Yamamoto S (1997) Liver volume in children measured by computed tomography. Pediatr Radiol 27(3):250-252
36. Oechtering D, Schiltmeyer B, Hempel G, Schwab M, Wurthwein G, Murdter T, et al (2005) Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation. Anticancer Drugs 16(3):337-344
37. Pawlowska AB, Blazar BR, Angelucci E, Baronciani D, Shu XO, Bostrom B (1997) Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 20(11):915-920
38. Poonkuzhali B, Srivastava A, Quernin MH, Dennison D, Aigrain EJ, Kanagasabapathy AS, et al (1999) Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 24(1):5-11
39. Schuler US, Renner UD, Kroschinsky F, Johne C, Jenke A, Naumann R, et al (2001) Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 114(4):944-950
40. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, et al (1997) Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89(8):3055-3060
41. Slattery JT, Risler LJ (1998) Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 20(5):543-549
42. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, et al (1995) Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16(1):31-42
43. Sobocinski KA, Thall PF, Bekele N (2004) Matched pairs analysis of IV vs. PO busulfan as a conditioning agent prior to transplantation. Blood (ASH Annual Meeting) 104, Abst. 349
44. Thall PF, Champlin RE, Andersson BS (2004) Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs. other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant 33(12):1191-1199
45. Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B, et al (2004) Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 10(11):805-812
46. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 79(9):2475-2479
47. Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A, et al (1996) Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 37(3):247-253
48. Vassal G, Mery-Mignard D, Caulin C (2003) Clinical trials in paediatric oncology. Recommendations for the development of new anticancer agents. Therapie 58(3):229-246
49. Vassal G, Tranchand B, Valteau-Couanet D, Mahe C, Couanet D, Schoeppfer C, et al (2001) Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma. Bone Marrow Transplant 27(5):471-477
50. Vassal G (1994) Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review). Anticancer Res 14(6A):2363-2370
51. Wall DA, Chan KW, Klemperer MR (1999) Phase II trial of intravenous busulfan (IV BU) and cyclophosphamide (Cy) in pediatric patients: preliminary pharmacokinetics. ASBMT, Abstract No. 80
52. Yeager AM, Wagner JE Jr, Graham ML, Jones RJ, Santos GW, Grochow LB (1992) Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 80(9):2425-2428
53. Yoshizumi T, Gondolesi GE, Bodian CA, Jeon H, Schwartz ME, Fishbein TM, et al (2003) A simple new formula to assess liver weight. Transplant Proc 35(4):1415-1420
54. Zwaveling J, Bredius RG, Cremers SC, Ball LM, Lankester AC, Teepe-Twiss IM, et al (2005) Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 35(1):17-23